Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmia syndrome or so-called 'channelopathy'. CPVT is characterised by the occurrence of adrenergic mediated polymorphic ventricular tachyarrhythmias (figure 1). 1 The prevalence of CPVT in the general population is unknown, but has been estimated at 1 in 10 000. Although a rare disease, recognition of CPVT is important because of its high mortality rate of up to 50% in severely affected untreated individuals up to the age of 20 years. 1 Accordingly, CPVT probably plays a significant role in autopsy negative, sudden unexplained death of young individuals, (w1) and sudden infant death syndrome (ie, sudden death of an infant under 1 year of age that remains unexplained after a death scene and medicolegal investigation, including a complete autopsy and clinical history review). 2 For the last 15 years, significant progress has been made in our understanding of genetic, pathophysiological, and clinical aspects of CPVT. The aim of this article is to offer a perspective on molecular genetics, disease pathogenesis, clinical and genetic diagnosis, therapeutic strategies, and prognosis in CPV
Keywords

This publication has 19 references indexed in Scilit: